Effects of sulfasalazine treatment on serum immunoglobulin levels in children with juvenile chronic arthritis

Scandinavian Journal of Rheumatology

Volumn 30, Issue 1, 2001, Pages 25-30

  Dijkmans, B A C ^a   Van Rossum, M A J ^b   Van Soesbergen, R M ^c   Fiselier, T J W ^d   Franssen, M J A M ^e   Ten Cate, R ^f   Van Suijlekom Smit, L W A ^f   Wulffraat, N M ^g   Van Luijk, W H J ^h   Oostveen, J C M ⁱ   Kuis, W ^g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Sint Maartensklinik   (Netherlands)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

Adverse events; Dysimmunoglobulinemia; Juvenile chronic arthritis; Serum immunoglobulin levels; Sulfasalazine

Indexed keywords

CORTICOSTEROID; GOLD; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDUCED DISEASE; DYSGAMMAGLOBULINEMIA; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS; DYSGAMMAGLOBULINEMIA; FEMALE; HUMANS; IMMUNOGLOBULINS; INFANT; SULFASALAZINE;

EID: 17744383754     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097401750065283     Document Type: Article

References (39)

1. Sulphasalazine in rheumatoid arthritis
2. Sulfasalazine in rheumatoid arthritis: A double-blind, placebo-controlled trial
3. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: Evidence of an earlier effect of sulphasalazine
4. Sulfasalazine in early rheumatoid arthritis: A 48 week double-blind, prospective, placebo-controlled study
5. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: A preliminary open trial
6. Die therapie der juvenilen chronischen arthritis mit sulfasalazin
7. A multicenter pilot study of sulphasalazine in juvenile chronic arthritis
8. Sulfasalazine treatment in juvenile chronic arthritis: An open study
9. Die behandlung der juvenilen spondylarthritis und der reaktiven arthritis mit sulfasalazin
10. Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis
11. Sulfasalazine treatment for juvenile spondylarthropathy
12. Sulfasalazine therapy for juvenile rheumatoid arthritis
13. Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
14. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis
15. Sulfasalazine: Mechanism of action in rheumatoid arthritis
16. Soluble cell adhesion molecules - P-selection and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis
17. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: Adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status
18. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis
19. Evidence for differential effects of sulfasalazine on systemic and mucosal immunity in rheumatoid arthritis
20. Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis
21. Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalazine therapy in rheumatoid arthritis
22. Guidelines for monitoring drug therapy in rheumatoid arthritis
23. Laboratory screening for side effects of disease modifying antirheumatic drugs in daily rheumatological practice
24. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997
25. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease
26. Sulphasalazine induced immunodeficiency
27. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy
28. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis
29. In vitro immunomodulatory effects of sulfasalazine and its metabolites
30. Effect of sulfasalazine on B cell hyperactivity in patients with reumatoid arthritis
31. Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis
32. Persistent and transient IgA deficiency in juvenile rheumatoid arthritis
33. Selective IgA deficiency and autoimmunity
34. Occurrence of selective IgA deficiency in children with juvenile rheumatoid arthritis
35. Immune abnormalities in the pathogenesis of juvenile rheumatoid arthritis
36. Juvenile rheumatoid arthritis and the trimolecular complex (HLA, T cell receptor, and antigen)
37. Common variable immunodeficiency is associated with polymorphic markers in the human major histocompatibility complex
38. Role of immunoglobulin subclasses and specific antibody determinations in the evaluation of recurrent infection in children
39. Defective anti-pneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections